- Home
- PNI vs NRXS Comparison
PNI vs NRXS Comparison
Compare PNI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PNI | NRXS |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PNI | NRXS |
|---|---|---|
| Price | $7.00 | $8.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 40.4K | ★ 164.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $6.43 | $1.95 |
| 52 Week High | $7.20 | $8.40 |
Technical Indicators
Market Signals| Indicator | PNI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 69.30 |
| Support Level | $6.88 | $6.67 |
| Resistance Level | $7.07 | N/A |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 73.68 | 83.01 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).